Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers
Reimbursement Give And Take
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
You may also be interested in...
Join the Pink Sheet's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
The Chugai/Roche antibody has been filed for PNH in Japan as more details of its Phase III results are released.